CD14+ monocytes contribute to inflammation in chronic nonbacterial osteomyelitis (CNO) through increased NLRP3 inflammasome expression

Brandt D., a, 1
Sohr E., a 1
Pablik J.
Schaabel A.
Kappelhagen R.
Mabet K.
Girsch H.
Morbach H.
Thielemann C.
Hofmann S.R.
Hedrich C.M.

Christian.hedrich@liverpool.ac.uk

1These authors contributed equally to the presented work.

Abstract

The pathophysiology of chronic nonbacterial osteomyelitis (CNO) remains incompletely understood. Increased NLRP3 inflammasome activation and IL-1β release in monocytes from CNO patients was suggested to contribute to bone inflammation. Here, we dissect immune cell infiltrates and demonstrate the involvement of monocytes across disease stages. Differences in cell density and immune cell composition may help to discriminate between BOM and CNO. However, differences are subtle and infiltrates vary in CNO. In contrast to other cells involved, monocytes are a stable element during all stages of CNO, which makes them a promising candidate in the search for “drivers” of inflammation. Furthermore, we link increased expression of inflammasome components NLRP3 and ASC in monocytes with site-specific DNA hypomethylation around the corresponding genes NLRP3 and PYCARD. Our observations deliver further evidence for the involvement of pro-inflammatory monocytes in the pathophysiology of CNO. Cellular and molecular alterations may serve as disease biomarkers and/or therapeutic targets.
1.1 Introduction

Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disorder. While all age groups can be affected, peak onset ranges between 7 and 12 years. A subset of CNO patients develops inflammatory lesions in single bones that can sometimes be timely limited. Most patients, however, experience chronic recurrent courses with more or less symmetric lesions at multiple sites. Such courses are usually referred to as chronic recurrent multifocal osteomyelitis (CRMO) [1-3]. Particularly cases with high disease activity, and/or delayed diagnosis and treatment initiation are prone to develop additional inflammatory symptoms, including palmoplantar pustulosis, arthritis or bowel inflammation. Some patients experience severe sequelea, such as vertebral body fractures. Timely diagnosis and initiation of effective treatment can be challenging in individual cases caused by the absence of prospectively tested disease biomarkers or diagnostic criteria [3,4]. Thus, CNO/CRMO remains a diagnosis of exclusion that requires the consideration of differential diagnoses, including infectious osteomyelitis, malignancies and other rare conditions (such as the metabolic bone disease hypophosphatasia and other autoinflammatory conditions). In unclear cases, differential diagnoses, namely bone infection or malignancies, require to be excluded through bone biopsies [2,3,5].

To date, the exact molecular pathophysiology of CNO/CRMO remains unknown. Descriptive analyses of bone biopsies suggest the presence of more or less distinct disease stages [2,6-7]. “Early lesions” suggest a central contribution of innate immune cells, namely neutrophils and monocytes, in disease pathophysiology, while “later stage” bone biopsies are characterized by infiltrates of lymphocytes and plasma cells. However, based on the rarity of CNO, the fact that only a relatively small subset of patients requires diagnostic bone biopsies, and lastly and most importantly the fact that the interval between disease-onset and bone biopsy remains unclear in all cases, a clear definition of “early” vs. “late” was impossible, and mostly based on the visual impression in histopathological samples. The presence of innate immune cells particularly in presumably “early lesions”, contributed to the conclusion, that CNO/CRMO is an autoinflammatory bone disorder. However, the contribution of adaptive immune cells in “late phase” bone lesions has not been investigated and remains elusive.

While the exact molecular pathophysiology of CNO is incompletely understood, recent data suggest reduced IL-10 expression and uninhibited NLRP3 inflammasome activation in monocytes from CNO patients as central contributors to bone inflammation and resulting clinical symptoms [8-10]. Scianaro et al. (2014) detected increased mRNA expression of IL-1β and NLRP3 inflammasome components NLRP3 (NLRP3 gene), ASC (PYCARD gene) and caspase-1 (CASPI gene) in PBMCs from active CRMO patients [11]. We recently demonstrated increased IL-1β expression and release in monocytes from CRMO patients [8]. Furthermore, we and others identified NLRP3 and IL-1β protein in inflamed bone regions from CRMO patients [8]. Whether monocytes or other immune cells (e.g. neutrophils) are a source of these proteins and whether individual cells produce increased amounts of NLRP3 inflammasome-associated mediators remained unclear. Furthermore, the exact molecular mechanisms that contribute to increased inflammasome expression and resulting IL-1β activation and release remained unknown.

In the present study, we aimed to investigate immune cell infiltrates in bone biopsies from CRMO patients, particularly the presence of monocytes at different disease stages, to assess their potential contribution to both early and chronic bone inflammation. Furthermore, we examined the expression of pro-inflammatory IL-1β, and NLRP3 inflammasome-associated genes (NLRP3, CASPI, PYCARD) in monocytes and DNA methylation patterns that may contribute to gene dysregulation in CNO/CRMO [8].

2.2 Materials and Methods

2.2.1 Patients and controls

All patients with CNO/CRMO or bacterial osteomyelitis (BOM) included in this study were diagnosed at the Department of Pediatrics, Universitätsklinikum Carl Gustav Carus, TU Dresden, Dresden, Germany or University Children's Hospital Würzburg, University of Würzburg, Würzburg, Germany. Bone tissue was collected during routine diagnostic workup (CNO/CRMO and BOM) or during elective bone osteomyelitis procedures. Lithium heparin blood was collected from treatment naïve CRMO patients and healthy controls (patients undergoing elective surgery) for the isolation of monocytes. The use of tissue from routine bone biopsies, immune staining, collection of blood samples and immune cell isolation and use was permitted by local ethics committees.

2.2.2 Immunohistochemistry

Paraffin embedded bone samples from 4 CNO patients, 3 patients with bacterial osteomyelitis (BOM) as disease controls, and 2 healthy individuals were decalcified, and mounted on slides in preparation for antibody staining. Demographics of CNO/CRMO patients, bacterial osteomyelitis patients and controls were comparable. None of the patients received systemic treatment other than NSAID at the time of surgery.

Slides were processed using the Ventana Benchmark ultra-automated system with proprietary reagents (Roche/Ventana Medical Systems). Heat induced antigen retrieval method was used in Cell Conditioning solution (CC1; Roche/Ventana). The following antibodies were used for immunostaining: anti-CD14 (Ventana/Roche; EPR 3653) for monocytes, anti-CD15 (Cell Marque; MMA) for neutrophils, anti-CD138 (Cell Marque; B-A38) for plasma cells, anti-
CD20 (DAKO; L26) for B lymphocytes, and anti-CD3 (Ventana; 2GV6) for T lymphocytes. Antibody detection was performed using UltraView universal DAB and UltraView universal alkaline phosphatase red kit (Roche/Ventana). Hematoxylin II and bluing reagent (Ventana/Roche) were used for chromogenic counterstaining following standard protocols. Cell numbers were determined in 4–10 visual fields (32,188.77 μm²) per individual adding up to 36 in CNO, 25 in BOM, and 12 in the control group. The number of investigated visual fields per individual depended on the presence and size of bone lesions in the mounted tissue and sample quality.

2.3.2.3 Cell isolation and culture

Peripheral blood mononuclear cells (PBMCs) were collected by density gradient centrifugation (Lymphoprep, Nycomed). From PBMCs, CD14+ monocytes were isolated by negative selection (Stemcell Technologies). Monocytes were cultured at a concentration of 1x10⁶ cells/mL in DMEM with 10% FCS. Some cells were treated with lipopolysaccharide (10 ng/mL) for 16 h. Cells were harvested for subsequent qRT-PCR and DNA methylation analyses as indicated.

2.4.2.4 Real-time PCR

Semi-quantitative real-time PCR (qRT-PCR) was performed in samples from 6 CNO/CRMO patients and 6 controls, using GoTaq qPCR Master Mix Real time PCR system (Promega) according to manufacturer's instructions. Results were normalized to GAPDH and a calibrator of pooled human cDNA derived from ex vivo isolated “untouched” CD14+ monocytes (Stemcell Technologies) included on all PCR plates. Real-time PCR data were analyzed using the comparative CT method [12].

2.5.2.5 Western blotting

Resting or LPS stimulated (see above) CD14+ monocytes (Stemcell Technologies) from 4 CNO/CRMO patients and 4 controls were lysed and processed as reported previously [13]. After centrifugation (16,400 g; 30min; 4°C), supernatants were collected and an identical amount of protein from each lysate (5 μg/well) was separated on NuPAGE 4%–12% Bis-Tris Gel (Life Technologies). Proteins were transferred to a nitrocellulose membrane, which was subsequently blocked for 1 hour using 2% BSA in PBS and incubated at room temperature with anti-NLRP3 (AG-20B-0014, AdipoGen), anti-IL-1β (sc-7884, Santa Cruz), anti-ASC (AL177, AdipoGen), anti-caspase-1 (sc-622, Santa Cruz), and anti-GAPDH (H86504M-BU, Meridian Life Science). The membrane was washed with TBS-T and incubated with a 1:3,000 dilution of secondary antibody (goat anti-mouse IgG or donkey anti-rabbit IgG) coupled with HRP (Jackson Immunoresearch). The Imaging System c300 (Azure Biosystems) was used for detection.

2.6.2.6 DNA methylation qPCR

Mouse and human IL1B, NLRP3, and PYCARD genes were aligned, and conserved non-coding sequences (CNS) regions were determined (VISTA Genome Browser). CNS regions were defined as regions with sequence homology of over 75% between the human and mouse genes over at least 200 base pairs. Based on the degree of conservation, distribution of CpG sequences and the presence of methylation-sensitive restriction sites (MSRE sites), five regions of interest were identified across the genes (Figure 4A-C). OneStep qMethyl kit (Zymo Research) was used as a real-time procedure for the determination of DNA methylation of specific sequences by MSRE digestion and quantitative polymerase chain reaction (PCR), following manufacturer's instructions. Human genomic DNA derived from ex vivo isolated “untouched” CD14+ monocytes from 6 CNO/CRMO patients and 6 controls was used as template.

2.7.2.7 Statistical analysis

Statistical analysis was performed using STATA 12.0 software (StataCorp, College Station, TX, USA). Non-parametric tests were used due to small sample size and skewness of our data. Differences between two groups were analyzed using two-tailed Wilcoxon rank-sum (Mann-Whitney) tests for continuous variables. Kruskal-Wallis test was used to evaluate significance between independent variables of three groups. For all analyses, two-sided p values of <0.05 were considered statistically significant.

3.3 Results

3.4.3.1 Immune infiltrates in CNO/CRMO

The composition of immune cell infiltrations was determined in bone biopsies from CNO/CRMO patients, BOM patients, and healthy controls (children undergoing osteotomy) (Figure 1). In line with the existing literature, immune cell infiltrates in CNO/CRMO patients were variable, potentially reflecting different disease stages. Based on immune cell infiltrates, and definitions from previous reports, we divided investigated power fields (32,188.77 μm² each) in three groups based on their visual appearance in hematoxylin and eosin (HE) stains: i) “early phase noninfectious osteomyelitis” with mainly segmented nuclear cells (neutrophils) and large mononuclear (monocyte) infiltrates, ii) “mixed pattern” infiltrates with small mononuclear blood cells (lymphocytes) and interspersed conglomerates of neutrophils and monocytes, and iii) “late phase noninfectious osteomyelitis” with mostly lymphocyte infiltrates (Figure 1A).
Next, we performed a cell count in all included power fields, and determined the number of cells and the proportion of monocytes (CD14+), neutrophils (CD15+), T lymphocytes (CD3+), B lymphocytes (CD20+), and plasma cells (CD138+) as a fraction of all nucleated cells in the area (Figures 1, 2). Significant differences in absolute numbers of monocytes \( (p<0.0001) \), neutrophilic granulocytes \( (p<0.0001) \), T lymphocytes \( (p<0.0001) \), B lymphocytes \( (p<0.0002) \) and plasma cell \( (p<0.0001) \) have been detected between BOM, CNO and healthy controls with increased counts in both included forms of osteomyelitis (Table 1).
Quantification of immune cell distribution in BOM, CNO/CRMO and controls. Paraffin embedded bone samples from 4 CRMO patients (36 power fields), 3 patients with bacterial osteomyelitis (25 power fields) as disease control, and 2 healthy individuals (12 power fields) were used for immune cell quantification through immune histochemistry. Absolute numbers (left panel) and proportions of immune cells relative to all nucleated cells in the power field (right panel) were determined. In bacterial (BOM) and chronic nonbacterial osteomyelitis (CNO) monocyte (A), neutrophil (B), T cell (C), B cell (D), and plasma cell (E) counts were increased as compared to controls. Numbers of B lymphocytes were only significantly increased in BOM (D) as compared to healthy bone, while numbers were not significantly increased in CNO (*p < 0.05; **p < 0.01, ***p < 0.001).

Table 1: Quantification of tissue immune cells

<table>
<thead>
<tr>
<th>Cell type</th>
<th>Absolute numbers: CNO vs. BOM vs. controls (Fig. 2, left panel)</th>
<th>Immune cells relative to nucleated cells: BOM vs. CNO (Fig. 2, right panel)</th>
</tr>
</thead>
<tbody>
<tr>
<td>monocytes (CD14⁺)</td>
<td>p &lt; 0.001</td>
<td>p &lt; 0.05</td>
</tr>
</tbody>
</table>
Increased expression of NLRP3 inflammasome-associated genes in CNO/CRMO. Based on findings from previous reports and the observations in Figure 1, monocytes are likely to be central players in the immune pathogenesis of CNO/CRMO. To assess their potential contribution to bone inflammation, we monitored mRNA (Figure 3A) and protein (Figure 3B, Supplement 2A) expression of IL-1, NLRP3, caspase-1, and ASC (PYCARD gene). Expression of IL-1β was increased in monocytes from CNO/CRMO patients under resting conditions and in response to stimulation with TLR4 ligand LPS on the mRNA level and increased on the protein level after stimulation. Furthermore, secretion of mature IL-1β was increased in both resting and stimulated (LPS) monocytes from CNO/CRMO patients when compared to controls (Supplement 2B). Expression of NLRP3 mRNA and protein was increased in monocytes from CNO/CRMO patients in response to stimulation when compared to monocytes from controls. Other than in a previous study that targeted mRNA expression in PBMCs from CNO/CRMO patients, caspase-1 mRNA expression was comparable in monocytes from CRMO patients and controls. However, there was a trend towards increased protein expression in cells from CNO/CRMO patients. The mRNA expression of the adapter molecule ASC (PYCARD) was increased in monocytes from CRMO patients after stimulation.

DNA Methylation patterns in monocytes from CNO/CRMO patients - Previous studies suggested altered epigenetic marks to contribute to altered cytokine expression in CNO [8,10]. To investigate site-specific DNA methylation patterns across the (between CNO patients and controls) differentially expressed human IL1B, NLRP3, and PYCARD genes, we applied bioinformatics approaches to define regions of interest (ROI, Figure 4A-C). Using the Vista genome browser inline tool (http://pipeline.lbl.gov/cgi-bin/gateway2), we aligned mouse and human IL1B, NLRP3, and PYCARD genes to identify conserved non-coding sequences (CNS; pink), exons (blue) and untranslated regions (UTR; turquoise). Here, CNS sites were defined as regions with sequence homology of >75% between human and mouse over a length of at least 200 bp. CNS, UTR or exons were defined ROIs when Cpg sequences (black filled circles below alignments in Figure 4A-C) were present and DNA sequences included methylation-sensitive restriction sites (MSRE sites) that allowed the chosen PCR based analytic approach (OneStep qMethyl kit, Zymo Research).
Expression of NLRP3 inflammasome-associated genes in monocytes from CNO/CRMO patients. A) We determined mRNA expression of IL-1β, NLRP3, caspase-1, and ASC (encoded by PYCARD) in unstimulated and stimulated (LPS) monocytes from CRMO patients and matched controls. Monocytes from CRMO patients express increased levels of IL-1β as compared to controls under resting conditions and in response to stimulation. Furthermore, expression of inflammasome components NLRP3 and ASC is increased in monocytes from CRMO patients after stimulation with LPS. No significant differences were seen in caspase-1 expression. B) Protein expression was monitored in monocytes from 4 CRMO patients and 4 controls (densitometry, normalized to GAPDH expression). Samples from one experiment (including one CNO/CRMO patient and one matched control), are connected by dotted lines. NLRP3 and IL-1β protein expression were increased in monocytes from CRMO patients in response to stimulation. Furthermore, we determined a trend towards increased expression of ASC in CRMO monocytes under all conditions, and a trend towards increased caspase-1 protein expression in monocytes from CRMO patients in cells stimulated with LPS.
While no significant differences were determined between ROI1 and 2 of the *IL1B* gene, ROI1 of *NLRP3* and ROI1 and 2 of *PYCARD* exhibited significantly reduced DNA methylation levels in monocytes from CROMO patients as compared to cells from matched healthy controls. No differences were determined between ROI1 and 2 of the *IL1B* gene.

For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.
4.4 Discussion

Chronic nonbacterial osteomyelitis has been classified as an autoinflammatory bone disorder because of the involvement of spontaneous activation of innate immune mechanisms in its pathophysiology [1,3,14,15]. A central step on the way was the descriptive analysis of immune cell infiltrates in bone biopsies from CNO/CRMO patients. To date, it is appreciated that immune infiltrates involve innate immune cells, particularly during "early" disease stages that are replenished or complemented by lymphocytes and plasma cells in “latter” disease stages [2,7]. However, none of the available reports provide exact quantification of immune cells and mostly rely on the description of morphologic features in HE stains. In a first step, we quantified immune cells in bone lesions of BOM vs. CNO/CRMO patients as compared to healthy bone tissue. Immune cell infiltrates were denser in BOM as compared to CNO/CRMO with higher absolute and relative numbers of monocytes, neutrophils, T and B lymphocytes. They furthermore, exhibited significant differences in immune cell numbers as compared to healthy controls (Table 1). Next, we for the first time quantified immune cell infiltrates in bone biopsies from CNO/CRMO patients at various disease stages (“early” vs. “late” stage) and compared findings to bone from healthy individuals (osteotomy) or bacterial osteomyelitis (BOM). Biopsies taken at any stage contained monocytes, neutrophils, T and B lymphocytes, and plasma cells. However, “early” stage inflammation was characterized by increased absolute numbers of monocytes, and B lymphocytes as compared to later stages. Furthermore, neutrophilic granulocyte, B and T lymphocyte proportions were elevated in “earlier” stages of CNO as compared to chronic stages. Only plasma cells appeared to increase in numbers over time and were more prevalent in “late”-appearing bone lesions. However, since plasma cells are also prevalent in bone samples from BOM patients, the sometimes-used term “plasma cellular” osteomyelitis for CNO/CRMO appears somewhat misleading, since plasma cellular infiltrates are also present in BOM and therefore not specific to CNO/CRMO. Indeed, dense plasma cell infiltrates should trigger the consideration of differential diagnoses, such as lymphoma. Here reported observations provide evidence for a coexistence of various “disease stages” or rather mutual involvement of innate and adaptive immune components in bone inflammation during both CNO/CRMO and BOM, thus underscoring that innate and adaptive immune responses cannot be seen as individual events. Furthermore, the coexistence of innate (monocytes and neutrophils) and adaptive (lymphocyte) immune cell infiltrates in CNO/CRMO may also suggest a central contribution of innate immune cells to maintaining inflammation, disease flares or phases with enhanced disease activity [16]. This may be in analogy to Muaro micro-abscesses in psoriasis, a disorder associated with CNO/CRMO that also may share molecular pathomechanisms. Muaro micro-abscesses are local infiltrates of neutrophils in the epidermis of psoriasis patients that are considered to promote skin inflammation and/or trigger flares in plaque psoriasis [17,18].

The constitutive and almost unchanged presence of monocytes in morphologically diverse infiltrates in CNO/CRMO may not only suggest ongoing interplay between components of the innate and adaptive immune response, but also suggests a central contribution of monocytes to disease pathology. This is further supported by the previous observation that monocytes from CRMO patients express and release increased amounts of pro-inflammatory IL-1β [8]. The exact molecular mechanisms that contribute to increased gene expression and activation, however, remained unknown. In the present study, we provide evidence for increased mRNA and protein expression of inflammasome associated NLRP3, ASC, and IL-1β. Increased abundance of inflammasome components NLRP3 and ASC, as well as the caspase-1 substrate IL-1β contribute to enhanced inflammasome assembly and subsequent IL-1β activation and release [19,20]. Of note, intracellular protein levels of IL-1β may even underestimate the total extent of IL-1β expression in monocytes, since activated mature IL-1β is secreted to the extracellular compartment, which is also significantly increased in monocytes from CNO/CRMO patients (as seen in Supplement 1B).

Methylation of CpG dinucleotides within DNA sequences resembles a potent mechanism to prevent recruitment of transcription factors and RNA polymerases to regulatory regions [21,22], thereby regulating gene expression. In previous studies, we demonstrated that altered epigenetic marks across the IL10 cytokine gene cluster contribute to impaired gene expression (8, 10). Thus, we tested whether disturbed epigenetic patterns may also contribute to increased NLRP3 inflammasome associated gene expression. Indeed, we provide evidence suggesting that reduced DNA methylation at highly conserved elements around the NLRP3 and ASC genes in monocytes from CNO/CRMO patients promote gene expression. This is in agreement with recent data from Vento-Tormo et al. (2017) who demonstrated that chronic inflammasome activation in a group of genetic inflammatory disorders referred to as cryopyrin-associated periodic syndromes (CAPS) is promoted by reduced DNA methylation, enhancing the transcription of inflammasome components [23]. Indeed, we detected increased mRNA expression of NLRP3 and ASC/PYCARD in monocytes from CNO/CRMO patients reflecting reduced DNA methylation. The IL1B gene, which is transcriptionally more active in samples from CNO/CRMO patients, exhibited comparable DNA methylation patterns between both groups at the sites investigated. More extensive DNA methylation mapping, including more distal elements may provide additional information. On the other hand, IL1B may be more resistant to changes in DNA methylation and be subject to dysregulation through additional events in monocytes from CRMO patients.

Currently, it remains unknown which molecular mechanisms mediate DNA demethylation at inflammasome-associated genes in monocytes from CNO/CRMO patients. It is tempting to speculate that reduced expression of immune regulatory cytokines IL-10 and IL-19 and the resulting dysbalance towards pro-inflammatory cytokine expression in monocytes from CNO/CRMO patients may mediate altered DNA methylation [8]. However, this remains to be determined in future studies and is beyond the scope of the study presented. Another possible contributor to DNA demethylation is the reduced activation of mitogen-activated protein kinases (MAPKs) ERK1 and 2 in monocytes from CRMO patients [9,10]. Indeed, T cells from patients with the autoimmune disorder systemic lupus erythematosus undergo DNA demethylation as a result of reduced protein kinase activation (involving MAPK), which centrally contributes to the pro-inflammatory effector phenotype of these cells [24,25].

compared to cells from matched healthy controls (Figure 4D).
The study presented is limited by the low numbers of patients and controls, which was caused by the rarity of the included diagnoses BOM and CNO, the fact that most patients with these diagnoses do not undergo routine bone biopsies, and difficulties identifying otherwise healthy individuals requiring osteotomy surgery (of note, osteopenic individuals were excluded). Future studies are warranted to confirm observations in larger cohorts and to address open questions of whether reduced expression of immune regulatory cytokines, increased expression of pro-inflammatory cytokines, other mechanisms such as altered MAPK activation, or a combination of the aforementioned contribute to DNA demethylation in monocytes from CRMO patients. For these investigations, international collaborations are required to allow the inclusion of larger cohorts with sufficient numbers of patients at different disease stages and with differential disease presentation. The recently published CARRA consensus treatment plan (CTP) initiative aiming at treatment harmonization and the comparison of available treatment options includes the collection of clinical datasets and biosamples [26]. Thus, it is a unique opportunity for international collaborations targeting the molecular pathophysiology of CNO/CRMO.

### 5.5 Conclusions

Cellular infiltrates in bacterial (BOM) and noninfectious CNO/CRMO include innate immune cells (neutrophils and monocytes) and lymphocytes. Generally, immune cell infiltrates are denser in BOM as compared to CNO/CRMO potentially reflecting higher inflammatory activity that may explain more acute onset of symptoms. In BOM and in “later stage” CNO lesions, plasma cells are present. Thus, discrimination between BOM and CNO solely based on histopathology remains difficult using currently available tools. Monocytes are prominent cellular components of inflammatory infiltrates in CNO/CRMO at all stages, which makes them a likely contributor to bone inflammation. Monocytes from CRMO patients express increased levels of NLRP3 inflammasome components NLRP3 and ASC, as well as IL-1β. Altered gene expression is promoted by site-specific DNA demethylation at the corresponding genes NLRP3 and PYCARD (ASC). Taken together, reported observations provide evidence for the involvement of monocytes in the immune pathogenesis of CNO and provide additional arguments for cytokine blocking strategies and/or inflammasome inhibition in CNO/CRMO refractory to standard treatment with NSAIDs.

Supplementary data to this article can be found online at 10.1016/j.clim.2018.04.011.

### Acknowledgements

The presented work was supported by the intramural MeDDrive program, University of Technology Dresden (grant no.: 60.364), the Fritz-Thyssen-Foundation (grant no.: 10.15.1.019MN) (to C.M.H.), and the Else-Krämer-Fresenius studentship program, University of Technology Dresden (to E.S.). The authors declare no competing interests relevant to the presented work.

### References


**E-Extra**

Morphological descriptions in the literature suggest that early stage biopsies of CNO patients and biopsies from BOM patients may be characterized by predominant infiltrates of neutrophils and monocytes. Thus, we used morphological appearance in HE stained to divide CNO samples in three groups (‘early’, ‘mixed pattern’, and ‘late’ stage CNO) (Figure 1, 2, Supplement 1). Absolute numbers of immune cells in samples from CNO, BOM patients and controls were compared and analyzed, applying Kruskal-Wallis tests. Significant differences between the three groups were present in the numbers of all immune cell types investigated: CD14+ monocytes, CD15+ neutrophilic granulocytes, CD3+ T lymphocytes, CD20+ B lymphocytes, and CD138+ plasma cells (Figure 2, left panel). Next, immune cells ratios as a fraction of nucleated cells within visual fields were compared between BOM and CNO using Wilcoxon rank-sum (Mann-Whitney) test (Figure 2, right panel). Normal controls were excluded from data sub-analysis, since low total cell numbers in visual fields
from healthy controls may have resulted in datasets of limited biological relevance. Relative numbers of monocytes (p<0.05), neutrophilic granulozytes (p<0.02) and plasma cells (p<0.02) based on the number of total nucleated cells were elevated in BOM as compared to CNO. Lastly, cell numbers and proportions in bone tissue from CNO patients with "early", "mixed pattern" or "late stage" bone changes were compared (Supplement 1). Differences in absolute cell numbers were detected in monocytes (p<0.05) and B lymphocytes (p<0.05), which were elevated in "early" CNO. Neutrophilic granulozyte (p<0.001), T cell (p<0.05), and B lymphocyte (p<0.002) proportions relative to the number of nucleated cells were elevated in "early" and "mixed pattern" CNO as compared to "late" stages. Plasma cells trended to be more common in "late" CNO as a proportion of nucleated cells. This, however, failed to reach statistical significance. As mentioned above, absolute and relative immune cell numbers were comparable between BOM and CNO tissue.

Increased expression of NLRP3 inflammasome-associated genes in CNO/CRMO. Based on findings from previous reports and the observations in Figure 1, monocytes are likely to be central players in the immune pathogenesis of CNO/CRMO. To assess their potential contribution to bone inflammation, we monitored mRNA (Figure 3A) and protein (Figure 3B, Supplement 2A) expression of IL-1, NLRP3, caspase-1, and ASC (PYCARD gene). Expression of IL-1β was increased in monocytes from CNO/CRMO patients under resting conditions and in response to stimulation with TLR4 ligand LPS on the mRNA level and increased on the protein level after stimulation. Furthermore, secretion of mature IL-1β was increased in both resting and stimulated (LPS) monocytes from CNO/CRMO patients when compared to controls (Supplement 2B). Expression of NLRP3 mRNA and protein was increased in monocytes from CNO/CRMO patients in response to stimulation when compared to monocytes from controls. Other than in a previous study that targeted mRNA expression in PBMCs from CNO/CRMO patients, caspase-1 mRNA expression was comparable in monocytes from CRMO patients and controls. However, there was a trend towards increased protein expression in cells from CNO/CRMO patients. The (mRNA) expression of the adapter molecule ASC (PYCARD) was increased in monocytes from CRMO patients after stimulation.

The constitutive and almost unchanged presence of monocytes in morphologically diverse infiltrates in CNO/CRMO may not only suggest ongoing interplay between components of the innate and adaptive immune response, but also suggests a central contribution of monocytes to disease pathology. This is further supported by the previous observation that monocytes from CRMO patients express and release increased amounts of pro-inflammatory IL-1β [8]. The exact molecular mechanisms that contribute to increased gene expression and activation, however, remained unknown. In the present study, we provide evidence for increased mRNA and protein expression of inflammasome associated NLRP3, ASC, and IL-1β. Increased abundance of inflammasome components NLRP3 and ASC, as well as the caspase-1 substrate IL-1β contribute to enhanced inflammasome assembly and subsequent IL-1β activation and release [19,20]. Of note, intracellular protein levels of IL-1β may even underestimate the total extend of IL-1β expression in monocytes, since activated mature IL-1β is secreted to the extracellular compartment, which is also significantly increased in monocytes from CNO/CRMO patients (as seen in Supplement 1B).

**Highlights**

- **E-component**

The following are the supplementary data related to this article.

**Multimedia Component 1**

**Supplement 1** Quantification on immune cell distribution in “early”, “mixed pattern” and “late” CNO/CRMO. Paraffin embedded bone samples from 4 CRMO patients (36 power fields), 3 patients with bacterial osteomyelitis (25 power fields) as disease control, and 2 healthy individuals (12 power fields) were used for immune cell quantification through immune histochemistry. Absolute numbers (left panel) and proportions of immune cells relative to all nucleated cells in the power field (right panel) were determined. Differences in absolute numbers of immune cells between the three groups of CNO samples (“early” CNO (eCNO); “mixed pattern” CNO (mCNO); “late stage” CNO (lCNO)) were detected in monocytes and B cells. Neutrophilic granulozyte and B cell proportions relative to the number of nucleated cells were elevated in “earlier” stages of CNO as compared to “late” stages. Plasma cells trended to be more common in “later” CNO stages. This, however, failed to reach statistical significance (*p<0.05; **p<0.01, ***p<0.001).

**Multimedia Component 2**

**Supplement 2** Expression of NLRP3 inflammasome-associated genes in monocytes from CNO/CRMO patients. A) Protein expression was monitored in monocytes from 4 CRMO patients and 4 controls. One representative Western blot is provided. B) Secretion of mature IL-1β protein from monocytes from CNO/CRMO patients and controls under resting conditions and in response to stimulation with LPS. In the upper panel, absolute values of IL-1β protein in the supernatant are displayed; the lower panel indicates fold increase of IL-1β protein secretion from monocytes based on unstimulated cells from healthy controls in each experiment. Median values, standard deviations, and p values from Mann-Whitney tests are provided.
• Immune infiltrates in CNO involve cells of the innate and adaptive immune system.
• Innate immune cells may drive flares in analogy to Munro abscesses in psoriasis.
• Monocytes are a stable and almost unchanged element of all CNO/CRMO stages.
• Monocytes from CNO patients over-express NLRP3, ASC, and IL-1β
• Gene expression is promoted by DNA hypomethylation at NLRP3 and PYCARD.

Queries and Answers

Query:
Your article is registered as belonging to the Special Issue/Collection entitled “Epigenetics”. If this is NOT correct and your article is a regular item or belongs to a different Special Issue please contact d.krishnan@elsevier.com immediately prior to returning your corrections.

Answer: Yes

Query:
Please confirm that given names and surnames have been identified correctly and are presented in the desired order, and please carefully verify the spelling of all authors’ names.

Answer: Christian Hedrich has an additional affiliation in the UK: Department of Paediatric Rheumatology, Alder Hey Children’s NHS Foundation Trust Hospital, Liverpool, UK

Query:
The author names have been tagged as given names and surnames (surnames are highlighted in teal color). Please confirm if they have been identified correctly.

Answer: Yes

Query:
Please provide the corresponding grant number(s) for the following grant sponsor(s): “University of Technology”.

Answer: There is no grant number available for the studentship.

Query:
Please provide the volume number and page range for the bibliography in Ref. [26].

Answer: Manuscript is ahead of print. This is all information available: Arthritis Care Res (Hoboken). 2017 Nov 7. doi: 10.1002/acr.23462. [Epub ahead of print]